CANbridge Pharmaceuticals Management

Management criteria checks 1/4

CANbridge Pharmaceuticals' CEO is James Qun Xue, appointed in Jan 2018, has a tenure of 6.33 years. total yearly compensation is CN¥13.12M, comprised of 37.9% salary and 62.1% bonuses, including company stock and options. directly owns 9.83% of the company’s shares, worth HK$14.83M. The average tenure of the management team and the board of directors is 2.6 years and 2.9 years respectively.

Key information

James Qun Xue

Chief executive officer

CN¥13.1m

Total compensation

CEO salary percentage	37.9%
CEO tenure	6.3yrs
CEO ownership	9.8%
Management average tenure	2.6yrs
Board average tenure	2.9yrs

Recent management updates

Recent updates

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05

CEO Compensation Analysis

How has James Qun Xue's remuneration changed compared to CANbridge Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CN¥379m
Sep 30 2023	n/a	n/a	-CN¥416m
Jun 30 2023	n/a	n/a	-CN¥453m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥13m	CN¥5m	-CN¥483m
Sep 30 2022	n/a	n/a	-CN¥733m
Jun 30 2022	n/a	n/a	-CN¥982m
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥10m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥828m
Dec 31 2020	CN¥6m	CN¥4m	-CN¥846m
Dec 31 2019	CN¥10m	CN¥3m	-CN¥218m

Compensation vs Market: James Qun's total compensation ($USD1.82M) is above average for companies of similar size in the Hong Kong market ($USD232.55K).

Compensation vs Earnings: James Qun's compensation has increased whilst the company is unprofitable.

CEO

James Qun Xue (53 yo)

6.3yrs

Tenure

CN¥13,118,000

Compensation

Dr. James Qun Xue, Ph D., M.B.A., has served as Chairman of the Board and Chief Executive Officer at CANbridge Pharmaceuticals Inc. since January 2018 and as an executive Director on June 21, 2021 and serv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Qun Xue	Founder	6.3yrs	CN¥13.12m	9.83% CN¥ 14.8m
Glenn Hassan	Chief Financial Officer	5.1yrs	no data	no data
Pauline Li	Senior VP of Clinical Development & Operations	2yrs	no data	no data
Qian Ma	Director of Legal & Compliance	2.9yrs	no data	no data
Stella Mao	Senior Director of Public Affairs	4.3yrs	no data	no data
Chris Chen	Vice President of Human Resources	no data	no data	no data
Gerald F. Cox	Chief Development Strategist & Interim Chief Medical Officer	4.8yrs	no data	no data
Marcelo Cheresky	Chief Commercial Officer	no data	no data	no data
Wei Zhang	Senior Director & Head of CMC China	less than a year	no data	no data
Rebecca Zhang	Senior Vice President of Regulatory Affairs	1.8yrs	no data	no data
Jeff Kou	Director and Head of Program Management & Clinical Operations	2.3yrs	no data	no data
Fannie Man	Mainland China Commercial Head & GM of Hong Kong and Macau	less than a year	no data	no data

2.6yrs

Average Tenure

55yo

Average Age

Experienced Management: 1228's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Qun Xue	Founder	6.3yrs	CN¥13.12m	9.83% CN¥ 14.8m
James Arthur Geraghty	Independent Non-Executive Director	5.8yrs	CN¥202.00k	0.16% CN¥ 248.5k
Peng Kuan Chan	Independent Non-Executive Director	2.9yrs	CN¥202.00k	no data
Edward Hu	Non-Executive Director	1.8yrs	no data	no data
Richard Gregory	Independent Non-Executive Director	4.1yrs	CN¥202.00k	no data
Guangping Gao	Member of Strategic Advisory Board	3.9yrs	no data	no data
Mark A. Goldberg	Member of Strategic Advisory Board	no data	no data	no data
Anthony Amato	Member of Scientific Advisory Board	1.8yrs	no data	no data
Kan Chen	Non-Executive Director	2.9yrs	no data	no data
Lan Hu	Independent Non-Executive Director	2.3yrs	CN¥208.00k	no data
Robert Colvin	Member of Scientific Advisory Board	1.8yrs	no data	no data
Jean Francis	Member of Scientific Advisory Board	1.8yrs	no data	no data

2.9yrs

Average Tenure

60yo

Average Age

Experienced Board: 1228's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

CANbridge Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

High number of new and inexperienced directors

Recent updates

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

New minor risk - Share price stability

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Consensus EPS estimates upgraded to CN¥1.05 loss

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Announces Results from its CAN106 Phase 1 Trial

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Announces Executive Changes

CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Phase 1B/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria in China

Canbridge Pharmaceuticals Inc. Announces Approval of Can108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Reports Positive Top-Line Can106 Phase 1 Data

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Inc. has completed an IPO in the amount of HKD 685.13718 million.

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age